المؤلفون: Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petris, Bastholt, Lars, Moreno Ramírez, David, Alexander M.M.

المساهمون: Universidad de Sevilla. Departamento de Medicina

مصطلحات موضوعية: Cutaneous melanoma, Tumour thickness, Excisional margins, Sentinel lymph node dissection, Interferon-a, Adjuvant treatment, Metastasectomy, Systemic treatmen

Relation: European Journal of Cancer, 126, 159-177.; http://doi.org/10.1016/j.ejca.2019.11.015; https://idus.us.es/handle//11441/146561

الاتاحة: https://idus.us.es/handle//11441/146561

المؤلفون: Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Basset-Seguin, Nicole, Bastholt, Lars, Bataille, Veronique, Del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria C, Forsea, Ana-Maria, Grob, Jean-Jacques, Hoeller, Christoph, Kaufmann, Roland, Kelleners-Smeets, Nicole, Lallas, Aimilios, Lebbé, Celeste, Lytvynenko, Bodhan, Malvehy, Josep, Moreno-Ramirez, David, Nathan, Paul, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Van Akkooi, Alexander C J, Vieira, Ricardo, Zalaudek, Iris, Lorigan, Paul

المصدر: Garbe , C , Amaral , T , Peris , K , Hauschild , A , Arenberger , P , Basset-Seguin , N , Bastholt , L , Bataille , V , Del Marmol , V , Dréno , B , Fargnoli , M C , Forsea , A-M , Grob , J-J , Hoeller , C , Kaufmann , R , Kelleners-Smeets , N , Lallas , A , Lebbé , C , Lytvynenko , B , Malvehy , J , Moreno-Ramirez , D , Nathan , P , Pellacani , G , Saiag , P , Stratigos ....

مصطلحات موضوعية: Adjuvant treatment, Cutaneous melanoma, DABRAFENIB PLUS TRAMETINIB, Excisional margins, HIGH-RISK MELANOMA, Interferon-alpha, LENTIGO MALIGNA MELANOMA, MOHS MICROGRAPHIC SURGERY, Metastasectomy, POSTOPERATIVE STEREOTACTIC RADIOSURGERY, PRIMARY CUTANEOUS MELANOMA, RANDOMIZED PHASE-III, SENTINEL-NODE BIOPSY, STAGE IV MELANOMA, SURGICAL EXCISION MARGINS, Sentinel lymph node dissection, Systemic treatment, Tumor thickness

الاتاحة: https://cris.maastrichtuniversity.nl/en/publications/adcdb010-8cac-48f0-9046-d49ab603d107
https://doi.org/10.1016/j.ejca.2022.04.018

المؤلفون: Garbe, Claus, Amaral, Teresa M.S., Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Bastholt, Lars, Bataille, Véronique, del Marmol, Véronique, Dréno, Brigitte, Fargnoli, Maria Concetta, Grob, Jean Jacques, Höller, Christoph, Kaufmann, Roland, Lallas, Aimilios, Lebbé, Célèste, Malvehy, Josep, Middleton, Mark R., Moreno-Ramirez, David, Pellacani, Giovanni, Saiag, Phillippe, Stratigos, Alexander John, Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M.M.

المساهمون: Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Aix-Marseille Université - Faculté des sciences médicales et paramédicales (AMU SMPM), Aix Marseille Université (AMU), Service de Dermatologie AP-HP Hôpital Saint-Louis, Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré AP-HP, Novartis Les Laboratories Pierre Fabre Berlin Mathematical School, BMS AbbVie Sanofi Pfizer Amgen Eisai GlaxoSmithKline, GSK Roche DUSA Pharmaceuticals Merck KGaA Meso Scale Diagnostics, MSD, C.G. reports receiving personal fees from Amgen, Pierre Fabre, Philogen and MSD, and reports receiving grants and personal fees from Novartis, NeraCare, BMS, Roche and Sanofi, outside the submitted work.T.A. reports receiving personal fees and other grants from BMS, Novartis, Pierre Fabre, Neracare and Sanofi, outside the submitted work.K.P. reports receiving personal fees from Novartis, Roche, Sanofi, Lilly, Leopharma, Pierre Fabre, Almirall and Celgene, outside the submitted work.A.H. reports receiving grants and personal fees from Amgen, BMS, MerckSerono, MSD / Merck, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, Sanofi-Genzyme, and Novartis Pharma, receiving personal fees from OncoSec and Sun Pharma, outside the submitted work.P.A. reports receiving personal fees from Amgen, MSD, Novartis, BMS and Roche, outside the submitted work.L.B. reports receiving grants from BMS, during the conduct of the study, personal fees from BMS, Novartis, Merck MSD, Roche, Incyte, Bayer, outside the submitted work.V.B. reports receiving personal fees from Novartis and Merck MSD, outside the submitted work.V.d.M. reports receiving personal fees from MSD, BMS and Sanofi, grants and personal fees from ABVIE, grants from Jansen, outside the submitted work.B.M. reports grants and personal fees from BMS, Roche, Fabre and Sanofi, personal fees from MSD, outside the submitted work.M.C.F. reports receiving grants and personal fees from Almirall, Leo Pharma, Novartis, Sanofi, Abbvie and Galderma, personal fees from Janssen, Lilly, UCB, Celgene, Pierre Fabre, Mylan, Medac Pharma, Roche, Sun Pharma, outside the submitted work.J.J.G. reports receiving personal fees from Amgen, MSD, Novartis, BMS, Roche, Pierre fabre, MercK / Pfizer, outside the submitted work.C.H. reports receiving personal fees from Amgen, MSD, Novartis, Incyte, BMS, Pierre Fabre, Roche, Sanofi, outside the submitted work.R.K. reports receiving grants and personal fees from Novartis and Roche, and grants from AbbVie, Amgen, Bionteck, BMS, Celgene, Galderma, Janssen, Leo, Lilly, Merck, MSD, Pierre Fabre, Regeneron and Wyeth, outside the submitted work.A.L. reports personal fees from Amgen, Novartis, BMS and, Sanofi grants and personal fees from Roche, outside the submitted work.C.L. reports receiving grants and personal fees from Bristol-Myers Squibb and Roche, personal fees from MSD, Novartis, Amgen, Avantis Medical Systems, Pierre Fabre, Pfizer, Incyte, outside the submitted work.J.M. reports personal fees from Amgen, personal fees from MSD, grants from Novartis, grants and personal fees from BMS, grants and personal fees from Roche, grants and personal fees from Almirall, personal fees from Sun Pharma, outside the submitted work.M.M. reports receiving personal fees from Amgen and BiolineRx, grants and personal fees from Roche and GSK, grants from Astrazeneca, personal fees and other from Novartis, Eisai, Array Biopharma (now Pfizer), Rigontec (acquired by MSD), and BMS, other from Millennium, Regeneron Pfizer, personal fees, non-financial support and other from Immunocore, Replimun and Merck / MSD, outside the submitted work.G.P. reports receiving personal fees from Novartis, personal fees from Sanofi, grants from Novartis, instruments from 3Gen, Vidix, Fotofinder and MAVIG GmbH, outside the submitted work.P.S. reports receiving personal fees from Amgen, MSD and Pierre Fabre / array, grants and personal fees from Novartis, NeraCare, BMS, Roche, and Sanofi, outside the submitted work.A.J.S. reports personal fees and/or research support from Novartis, Roche, BMS, Abbvie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Vieira has nothing to disclose.I.Z. reports receiving personal fees from Difa Cooper, MSD, Sanofi, Almirall Hermal, Novartis, Mylan and Sunpharma, grants and personal fees from Roche, outside the submitted work.A.M.M.E. reports receiving personal fees from Biocad, Biovent, BMS, CatalYm, Ellipses, GSK, Incyte, IO Biotech, ISA Pharmaceuticals, Merck GmbH, MSD, Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SkylineDx, Stellas, other from RiverD, SkylineDx, Theranovir, all outside the submitted work., ANR-16-IDEX-0007,NExT (I-SITE),NExT (I-SITE)(2016)

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-03228160 ; European Journal of Cancer, 2020, 126, pp.159-177. ⟨10.1016/j.ejca.2019.11.015⟩.

مصطلحات موضوعية: Adjuvant treatment, Cutaneous melanoma, Excisional margins, Interferon-α, Metastasectomy, Sentinel lymph node dissection, Systemic treatment, Tumour thickness, [SDV.CAN]Life Sciences [q-bio]/Cancer

Relation: info:eu-repo/semantics/altIdentifier/pmid/31866016; PUBMED: 31866016

الاتاحة: https://hal.science/hal-03228160
https://hal.science/hal-03228160v1/document
https://hal.science/hal-03228160v1/file/PIIS0959804919308342-1.pdf
https://doi.org/10.1016/j.ejca.2019.11.015

المؤلفون: Alisa Yamasaki, Michael P Wu, Kevin S. Emerick

المصدر: OTO Open
OTO Open, Vol 4 (2020)

مصطلحات موضوعية: medicine.medical_specialty, melanoma survival, melanoma outcomes, medicine.medical_treatment, lcsh:Surgery, 03 medical and health sciences, 0302 clinical medicine, medicine, 030223 otorhinolaryngology, Original Research, melanoma recurrence rate, business.industry, Cartilage, Melanoma, Wide local excision, external ear melanoma, lcsh:RD1-811, lcsh:Otorhinolaryngology, medicine.disease, lcsh:RF1-547, cartilage-sparing excision, melanoma excisional margins, medicine.anatomical_structure, Otorhinolaryngology, 030220 oncology & carcinogenesis, Surgery, Radiology, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d702b8c8d66d8f34103149a6d2b5e147
https://doi.org/10.1177/2473974x20903124

المؤلفون: Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Bastholt, Lars, Bataille, Veronique, Del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria Concetta, Grob, Jean-Jacques, Höller, Christoph, Kaufmann, Roland, Lallas, Aimilios, Lebbé, Celeste, Malvehy, Josep, Middleton, Mark, Moreno-Ramirez, David, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M M, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)

المساهمون: Garbe, Clau, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Bastholt, Lar, Bataille, Veronique, Del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria Concetta, Grob, Jean-Jacque, Höller, Christoph, Kaufmann, Roland, Lallas, Aimilio, Lebbé, Celeste, Malvehy, Josep, Middleton, Mark, Moreno-Ramirez, David, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Vieira, Ricardo, Zalaudek, Iri, Eggermont, Alexander M M, Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Aix-Marseille Université - Faculté des sciences médicales et paramédicales (AMU SMPM), Aix Marseille Université (AMU), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Ambroise Paré [AP-HP], Novartis Les Laboratories Pierre Fabre Berlin Mathematical School, BMS AbbVie Sanofi Pfizer Amgen Eisai GlaxoSmithKline, GSK Roche DUSA Pharmaceuticals Merck KGaA Meso Scale Diagnostics, MSD, C.G. reports receiving personal fees from Amgen, Pierre Fabre, Philogen and MSD, and reports receiving grants and personal fees from Novartis, NeraCare, BMS, Roche and Sanofi, outside the submitted work.T.A. reports receiving personal fees and other grants from BMS, Novartis, Pierre Fabre, Neracare and Sanofi, outside the submitted work.K.P. reports receiving personal fees from Novartis, Roche, Sanofi, Lilly, Leopharma, Pierre Fabre, Almirall and Celgene, outside the submitted work.A.H. reports receiving grants and personal fees from Amgen, BMS, MerckSerono, MSD / Merck, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, Sanofi-Genzyme, and Novartis Pharma, receiving personal fees from OncoSec and Sun Pharma, outside the submitted work.P.A. reports receiving personal fees from Amgen, MSD, Novartis, BMS and Roche, outside the submitted work.L.B. reports receiving grants from BMS, during the conduct of the study, personal fees from BMS, Novartis, Merck MSD, Roche, Incyte, Bayer, outside the submitted work.V.B. reports receiving personal fees from Novartis and Merck MSD, outside the submitted work.V.d.M. reports receiving personal fees from MSD, BMS and Sanofi, grants and personal fees from ABVIE, grants from Jansen, outside the submitted work.B.M. reports grants and personal fees from BMS, Roche, Fabre and Sanofi, personal fees from MSD, outside the submitted work.M.C.F. reports receiving grants and personal fees from Almirall, Leo Pharma, Novartis, Sanofi, Abbvie and Galderma, personal fees from Janssen, Lilly, UCB, Celgene, Pierre Fabre, Mylan, Medac Pharma, Roche, Sun Pharma, outside the submitted work.J.J.G. reports receiving personal fees from Amgen, MSD, Novartis, BMS, Roche, Pierre fabre, MercK / Pfizer, outside the submitted work.C.H. reports receiving personal fees from Amgen, MSD, Novartis, Incyte, BMS, Pierre Fabre, Roche, Sanofi, outside the submitted work.R.K. reports receiving grants and personal fees from Novartis and Roche, and grants from AbbVie, Amgen, Bionteck, BMS, Celgene, Galderma, Janssen, Leo, Lilly, Merck, MSD, Pierre Fabre, Regeneron and Wyeth, outside the submitted work.A.L. reports personal fees from Amgen, Novartis, BMS and, Sanofi grants and personal fees from Roche, outside the submitted work.C.L. reports receiving grants and personal fees from Bristol-Myers Squibb and Roche, personal fees from MSD, Novartis, Amgen, Avantis Medical Systems, Pierre Fabre, Pfizer, Incyte, outside the submitted work.J.M. reports personal fees from Amgen, personal fees from MSD, grants from Novartis, grants and personal fees from BMS, grants and personal fees from Roche, grants and personal fees from Almirall, personal fees from Sun Pharma, outside the submitted work.M.M. reports receiving personal fees from Amgen and BiolineRx, grants and personal fees from Roche and GSK, grants from Astrazeneca, personal fees and other from Novartis, Eisai, Array Biopharma (now Pfizer), Rigontec (acquired by MSD), and BMS, other from Millennium, Regeneron Pfizer, personal fees, non-financial support and other from Immunocore, Replimun and Merck / MSD, outside the submitted work.G.P. reports receiving personal fees from Novartis, personal fees from Sanofi, grants from Novartis, instruments from 3Gen, Vidix, Fotofinder and MAVIG GmbH, outside the submitted work.P.S. reports receiving personal fees from Amgen, MSD and Pierre Fabre / array, grants and personal fees from Novartis, NeraCare, BMS, Roche, and Sanofi, outside the submitted work.A.J.S. reports personal fees and/or research support from Novartis, Roche, BMS, Abbvie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Vieira has nothing to disclose.I.Z. reports receiving personal fees from Difa Cooper, MSD, Sanofi, Almirall Hermal, Novartis, Mylan and Sunpharma, grants and personal fees from Roche, outside the submitted work.A.M.M.E. reports receiving personal fees from Biocad, Biovent, BMS, CatalYm, Ellipses, GSK, Incyte, IO Biotech, ISA Pharmaceuticals, Merck GmbH, MSD, Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SkylineDx, Stellas, other from RiverD, SkylineDx, Theranovir, all outside the submitted work., Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Portuguese Air Force Health Care Direction [Lisbon, Portugal] (PAFHCD), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), Kiel University, Charles University [Prague] (CU), Odense University Hospital (OUH), King‘s College London, Université libre de Bruxelles (ULB), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), University of L'Aquila [Italy] (UNIVAQ), Assistance Publique - Hôpitaux de Marseille (APHM), Medizinische Universität Wien = Medical University of Vienna, Frankfurt University Hospital, Aristotle University of Thessaloniki, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Oxford, Hospital Universitario Virgen Macarena [Séville], University - Hospital of Modena and Reggio Emilia [Modena, Italy], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Athens Medical School [Athens], Universidade de Coimbra [Coimbra], Università degli studi di Trieste = University of Trieste, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Princess Máxima Center for Pediatric Oncology, Dupuis, Christine

المصدر: European journal of cancer, 126
European Journal of Cancer
European Journal of Cancer, Elsevier, 2020, 126, pp.159-177. ⟨10.1016/j.ejca.2019.11.015⟩
Garbe, C, Amaral, T, Peris, K, Hauschild, A, Arenberger, P, Bastholt, L, Bataille, V, del Marmol, V, Dréno, B, Fargnoli, M C, Grob, J J, Höller, C, Kaufmann, R, Lallas, A, Lebbé, C, Malvehy, J, Middleton, M, Moreno-Ramirez, D, Pellacani, G, Saiag, P, Stratigos, A J, Vieira, R, Zalaudek, I, Eggermont, A M M & European Dermatology Forum (EDF), European Association of Dermato-Oncology (EADO), European Organization for Research and Treatment of Cancer (EORTC) 2020, ' European consensus-based interdisciplinary guideline for melanoma. Part 2 : Treatment – Update 2019 ', European Journal of Cancer, vol. 126, pp. 159-177 . https://doi.org/10.1016/j.ejca.2019.11.015
European Journal of Cancer, 2020, 126, pp.159-177. ⟨10.1016/j.ejca.2019.11.015⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, [SDV]Life Sciences [q-bio], Systemic treatment, Primary diagnosis, 0302 clinical medicine, Dermatoscopy, Stage (cooking), Melanoma, Trametinib, Adjuvant treatment, Cutaneous melanoma, Excisional margins, Interferon-α, Metastasectomy, Sentinel lymph node dissection, Tumour thickness, Combined Modality Therapy, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Excisional margin, Confocal reflectance microscopy, Settore MED/35 - MALATTIE CUTANEE E VENEREE, medicine.drug, Diagnostic Imaging, medicine.medical_specialty, Consensus, Follow-up examinations, Sentinel lymph node, Mutation testing, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, AJCC classification, Internal medicine, medicine, Humans, European Union, Neoplasm Staging, Interdisciplinary Communication, Total body photography, business.industry, Cancer, Dabrafenib, Guideline, medicine.disease, Imaging diagnostics, Cancérologie, 030104 developmental biology, Sequential digital dermatoscopy, business

وصف الملف: 1 full-text file(s): application/pdf; application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472ee622116554ed30e9886843aec52c
https://pubmed.ncbi.nlm.nih.gov/31866016

المؤلفون: Alexander M.M. Eggermont, Ketty Peris, Jean-Jacques Grob, Mark R. Middleton, Philippe Saiag, Hubert Pehamberger, Alan Spatz, Axel Hauschild, Alexander J. Stratigos, Julia Newton-Bishop, Josep Malvehy, Claus Garbe

المصدر: Garbe, C, Peris, K, Hauschild, A, Saiag, P, Middleton, M, Bastholt, L, Grob, J-J, Malvehy, J, Newton-Bishop, J, Stratigos, A J, Pehamberger, H, Eggermont, A M & European Dermatology Forum (EDF) 2016, ' Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-Update 2016 ', European Journal of Cancer, vol. 63, pp. 201-217 . https://doi.org/10.1016/j.ejca.2016.05.005

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Skin Neoplasms, Systemic treatment, 0302 clinical medicine, Molecular Targeted Therapy, Melanoma, media_common, Adjuvant treatment, Cutaneous melanoma, Excisional margins, Interferon-α, Metastasectomy, Sentinel lymph node dissection, Tumour thickness, Prognosis, Combined Modality Therapy, Europe, Oncology, Molecular Diagnostic Techniques, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Immunotherapy, Settore MED/35 - MALATTIE CUTANEE E VENEREE, medicine.medical_specialty, Consensus, Sentinel lymph node, Antineoplastic Agents, Dermoscopy, 03 medical and health sciences, Predictive Value of Tests, medicine, Journal Article, media_common.cataloged_instance, Humans, European union, Neoplasm Staging, business.industry, General surgery, Cancer, Guideline, Cell Cycle Checkpoints, medicine.disease, Survival Analysis, Surgery, 030104 developmental biology, Lymph Node Excision, Skin cancer, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5350ccaf49048ad260480a479f2e3e
https://portal.findresearcher.sdu.dk/da/publications/4a8e09d6-0936-4e64-b9c7-2e26e9646a23

المؤلفون: Universidad de Sevilla. Departamento de Medicina, Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petris, Bastholt, Lars, Moreno Ramírez, David, Alexander M.M.

مصطلحات الفهرس: Cutaneous melanoma, Tumour thickness, Excisional margins, Sentinel lymph node dissection, Interferon-a, Adjuvant treatment, Metastasectomy, Systemic treatmen, info:eu-repo/semantics/article

URL: https://hdl.handle.net/11441/146561
http://doi.org/10.1016/j.ejca.2019.11.015
European Journal of Cancer, 126, 159-177.
http://doi.org/10.1016/j.ejca.2019.11.015